CLINUVEL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15 AUD | +0.40% |
|
-0.92% | -6.25% |
| Sales 2024 * | 89.47M 58.9M | Sales 2025 * | 98.61M 64.91M | Capitalization | 748M 493M |
|---|---|---|---|---|---|
| Net income 2024 * | 34M 22.38M | Net income 2025 * | 37M 24.36M | EV / Sales 2024 * | 6.28 x |
| Net cash position 2024 * | 187M 123M | Net cash position 2025 * | 219M 144M | EV / Sales 2025 * | 5.36 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
20.2
x | Employees | - |
| Yield 2024 * |
0.45% | Yield 2025 * |
0.5% | Free-Float | 79.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Clinuvel Pharmaceuticals Limited
More press releases
More news
| 1 day | +0.40% | ||
| 1 week | -0.92% | ||
| Current month | -5.66% | ||
| 3 months | +11.36% | ||
| 6 months | -14.29% | ||
| Current year | -6.25% |
1 week
14.52
15.88
1 month
14.5215.98
Current year
12.9617.20
1 year
12.9621.45
3 years
12.9644.67
5 years
12.9245.88
10 years
1.3045.88
| Managers | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
| Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 15 | +0.40% | 49 850 |
| 24-06-06 | 14.94 | +0.07% | 30,073 |
| 24-06-05 | 14.93 | +2.26% | 52,945 |
| 24-06-04 | 14.6 | -3.69% | 101,491 |
| 24-06-03 | 15.16 | -4.65% | 73,189 |
Delayed Quote Australian S.E., June 07, 2024 at 02:11 am EDT
More quotes
Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Companyâs pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.94
AUD
Average target price
25.6
AUD
Spread / Average Target
+71.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.25% | 498M | |
| +0.82% | 93.19B | |
| 0.00% | 39.62B | |
| -11.95% | 33.78B | |
| +64.77% | 26.82B | |
| -16.09% | 15.35B | |
| -6.15% | 13.13B | |
| -11.77% | 11.6B | |
| -49.19% | 10.26B | |
| +5.24% | 9.43B |
- Stock Market
- Equities
- CUV Stock
